a2sp Limited has developed Magic Tag® Immobilisation and Screening technology to enable a rapid, cost-effective chemical genomics approach to drug screening.

a2sp is using this technology to probe the landscape of known drugs to identify novel drug reprofiling opportunities for subsequent progression through preclinical development.

Magic Tag® technology is also being made available to academic and industrial customers interested in drug reprofiling, target- and off-target drug-protein interactions and for a range of small and macromolecule immobilisation needs.